bupropion and Cocaine-Related Disorders studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Research Excerpts

Excerpt	Relevance	Reference
"Case 1 describes the interaction of cocaine abuse sensitization in a patient who developed psychosis with a lower dosage of bupropion."	7.85	Cocaine Abuse, Traumatic Brain Injury, and Preexisting Brain Lesions as Risk Factors for Bupropion-Associated Psychosis. ( Barman, R; Detweiler, MB; Kumar, S; Pagadala, B, 2017)
"Bupropion hydrochloride is a dopamine and norepinephrine reuptake inhibitor which may be an effective treatment for cocaine dependence due to its ability to reverse deficits in dopaminergic functioning that occur in chronic cocaine users."	6.73	Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. ( Bholat, MA; Heinzerling, KG; Kao, UH; Ling, W; Rotheram-Fuller, E; Shoptaw, S; Wang, PC, 2008)
" Participants assigned to treatment as usual with concurrent smoking-cessation treatment received weekly individual smoking cessation counseling and extended-release bupropion (300 mg/d) during weeks 1-10."	5.19	A randomized trial of concurrent smoking-cessation and substance use disorder treatment in stimulant-dependent smokers. ( Bachrach, K; Brigham, GS; DeGravelles, E; Douaihy, A; Gardin, JG; Ghitza, U; Haynes, L; Hiott, B; Hodgkins, C; Kelly, TM; Kropp, F; Lewis, DF; Lindblad, R; Love, LD; McCann, M; Penn, P; Sharma, G; Sonne, SC; Theobald, J; VanVeldhuisen, P; Winhusen, TM, 2014)
"The effects of cocaine were examined prior to and during bupropion maintenance in nonopioid-dependent cocaine abusers."	5.09	Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers. ( Hameedi, F; Kosten, TR; McCance-Katz, FE; Oliveto, A; Petrakis, I; Singha, A, 2001)
" Although alcoholism has received the most attention, nicotine, heroin, and cocaine have all been shown to be influenced by heredity."	4.82	Anticraving medications for relapse prevention: a possible new class of psychoactive medications. ( O'Brien, CP, 2005)
"Case 1 describes the interaction of cocaine abuse sensitization in a patient who developed psychosis with a lower dosage of bupropion."	3.85	Cocaine Abuse, Traumatic Brain Injury, and Preexisting Brain Lesions as Risk Factors for Bupropion-Associated Psychosis. ( Barman, R; Detweiler, MB; Kumar, S; Pagadala, B, 2017)
"Despite animal studies having shown a generalisation of the bupropion cue to cocaine, this drug has been used in cocaine abuse with mixed results."	3.79	Bupropion perceived as a stimulant by two patients with a previous history of cocaine misuse. ( Corkery, JM; Gentili, F; Girardi, P; Kotzalidis, GD; Pompei, F; Schifano, F; Vento, AE, 2013)
"Bupropion hydrochloride is a dopamine and norepinephrine reuptake inhibitor which may be an effective treatment for cocaine dependence due to its ability to reverse deficits in dopaminergic functioning that occur in chronic cocaine users."	2.73	Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. ( Bholat, MA; Heinzerling, KG; Kao, UH; Ling, W; Rotheram-Fuller, E; Shoptaw, S; Wang, PC, 2008)
"Pathological gambling is substantially more prevalent among cocaine-dependent outpatients than in the general population."	2.69	Pathological gambling among cocaine-dependent outpatients. ( Carriero, NJ; Gorelick, DA; Hall, GW; Montoya, ID; Preston, KL; Takushi, RY, 2000)

Research

Studies (25)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Four Week Continuous Smoking Abstinence

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	14 (56.00)	29.6817
2010's	7 (28.00)	24.3611
2020's	4 (16.00)	2.80

Authors	Studies
Carroll, FI	1
Blough, BE	1
Abraham, P	1
Mills, AC	1
Holleman, JA	1
Wolckenhauer, SA	1
Decker, AM	1
Landavazo, A	1
McElroy, KT	1
Navarro, HA	1
Gatch, MB	1
Forster, MJ	1
Ciccarone, D	1
Shoptaw, S	2
Ware, OD	1
Sweeney, MM	1
Cunningham, C	1
Umbricht, A	1
Stitzer, M	1
Dunn, KE	1
Swinford-Jackson, SE	1
O'Brien, CP	2
Kenny, PJ	1
Vanderschuren, LJMJ	1
Unterwald, EM	1
Pierce, RC	1
Wightman, RS	1
Erowid, E	1
Erowid, F	1
Thyssen, S	1
Wheeler, M	1
Pulminskas, B	1
Olson, R	1
Green, TC	1
Barman, R	1
Kumar, S	1
Pagadala, B	1
Detweiler, MB	1
Hankosky, ER	1
Bush, HM	1
Dwoskin, LP	1
Harris, DR	1
Henderson, DW	1
Zhang, GQ	1
Freeman, PR	1
Talbert, JC	1
Vento, AE	1
Schifano, F	1
Gentili, F	1
Pompei, F	1
Corkery, JM	1
Kotzalidis, GD	1
Girardi, P	1
Winhusen, TM	1
Brigham, GS	1
Kropp, F	1
Lindblad, R	1
Gardin, JG	1
Penn, P	1
Hodgkins, C	1
Kelly, TM	1
Douaihy, A	1
McCann, M	1
Love, LD	1
DeGravelles, E	1
Bachrach, K	1
Sonne, SC	1
Hiott, B	1
Haynes, L	1
Sharma, G	1
Lewis, DF	1
VanVeldhuisen, P	1
Theobald, J	1
Ghitza, U	1
Heinzerling, KG	1
Rotheram-Fuller, E	1
Kao, UH	1
Wang, PC	1
Bholat, MA	1
Ling, W	1
Stoops, WW	1
Lile, JA	1
Glaser, PE	1
Hays, LR	1
Rush, CR	1
Horey, JT	1
Mariani, JJ	2
Cheng, WY	1
Bisaga, A	1
Sullivan, M	1
Nunes, E	2
Levin, FR	3
Bagley, SC	1
Yaeger, D	1
Poling, J	1
Oliveto, A	2
Petry, N	1
Sofuoglu, M	1
Gonsai, K	1
Gonzalez, G	1
Martell, B	1
Kosten, TR	2
Johnson, BA	1
Hahn, M	1
Hajek, T	1
Alda, M	1
Gorman, JM	1
Kampman, KM	1
Castaneda, R	1
Levy, R	1
Hardy, M	1
Trujillo, M	1
Hall, GW	1
Carriero, NJ	1
Takushi, RY	1
Montoya, ID	2
Preston, KL	2
Gorelick, DA	2
Koetzner, L	1
Deng, S	1
Sumpter, TL	1
Weisslitz, M	1
Abner, RT	1
Landry, DW	1
Woods, JH	1
McCance-Katz, FE	1
Singha, A	1
Petrakis, I	1
Hameedi, F	1
Rothman, R	1
Evans, SM	1
McDowell, DM	1
Brooks, DJ	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes[NCT01077024]	Phase 3	538 participants (Actual)	Interventional	2010-02-28	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

A combination of daily self-reported smoking data and weekly carbon monoxide levels were used to determine continuous abstinence during post-quit days 15 - 42. (NCT01077024)
Timeframe: Post-quit days 15-42

Point-prevalence Abstinence (Smoking Outcome)

Intervention	percentage of participants (Number)
Smoking-cessation Treatment + Substance Treatment as Usual	6.7
Substance-treatment as Usual	0.0

point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm (NCT01077024)
Timeframe: Week 10 assessment

Point-prevalence Abstinence (Smoking Outcome) 3 Month Visit

Intervention	percentage of participants (Number)
Smoking-cessation Treatment + Substance Treatment as Usual	25.5
Substance-treatment as Usual	2.2

Point-prevalence Abstinence (Smoking Outcome) 6 Month Visit

Intervention	percentage of participants (Number)
Smoking-cessation Treatment + Substance Treatment as Usual	19.1
Substance-treatment as Usual	3.0

point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm (NCT01077024)
Timeframe: 6 month visit

Stimulant-free Results at 3-month Visit

Intervention	percentage of participants (Number)
Smoking-cessation Treatment + Substance Treatment as Usual	13.1
Substance-treatment as Usual	3.7

At the 3-month follow-up visit, percentage of participants with a negative urine drug screen for stimulant use and no stimulant use days reported during the past 28 days based on Timeline Follow-back. (NCT01077024)
Timeframe: 3-month follow-up visit

Stimulant-free Results at 6-month Visit

Intervention	percentage of participants (Number)
Smoking-cessation Treatment + Substance Treatment as Usual	74.3
Substance-treatment as Usual	68.8

At the 6-month follow-up visit, percentage of participants with a negative urine drug screen for stimulant use and no stimulant use days reported during the past 28 days based on Timeline Follow-back. (NCT01077024)
Timeframe: 6 - months follow-up visit

Stimulant-free Weeks Assessed by Self-report and Twice-weekly Urine Drug Screens

Intervention	percentage of participants (Number)
Smoking-cessation Treatment + Substance Treatment as Usual	69.5
Substance-treatment as Usual	71.6

Stimulant-free week results (no cocaine, methamphetamine and amphetamine use) were obtained by combining the urine drug screens (UDS) and the self-reported Timeline Follow-Back (TLFB). At the group level, this outcome translates into the percentage of weeks in each study arm that are stimulant-free. (NCT01077024)
Timeframe: Week 16

Article	Year
Understanding Stimulant Use and Use Disorders in a New Era. The Medical clinics of North America, 2022, Volume: 106, Issue:1 Topics: Adrenergic alpha-2 Receptor Antagonists; Adult; Anticonvulsants; Behavior Therapy; Bupropion; Centra	2022
Psychostimulant treatment of cocaine dependence. The Psychiatric clinics of North America, 2012, Volume: 35, Issue:2 Topics: Amphetamines; Animals; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Clinical	2012
Anticraving medications for relapse prevention: a possible new class of psychoactive medications. The American journal of psychiatry, 2005, Volume: 162, Issue:8 Topics: Alcoholism; Behavior, Addictive; Bupropion; Cocaine-Related Disorders; Disulfiram; Humans; Naltrexon	2005

Article	Year
Bupropion Slow Release vs Placebo With Adaptive Incentives for Cocaine Use Disorder in Persons Receiving Methadone for Opioid Use Disorder: A Randomized Clinical Trial. JAMA network open, 2023, 03-01, Volume: 6, Issue:3 Topics: Bupropion; Cocaine; Cocaine-Related Disorders; Dopamine Uptake Inhibitors; Humans; Male; Methadone;	2023
A randomized trial of concurrent smoking-cessation and substance use disorder treatment in stimulant-dependent smokers. The Journal of clinical psychiatry, 2014, Volume: 75, Issue:4 Topics: Adult; Amphetamine-Related Disorders; Antidepressive Agents, Second-Generation; Bupropion; Cocaine-R	2014
Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. Journal of addictive diseases, 2008, Volume: 27, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cocaine-Related Disorders; Cognitive Beh	2008
Influence of acute bupropion pre-treatment on the effects of intranasal cocaine. Addiction (Abingdon, England), 2012, Volume: 107, Issue:6 Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Bupropion; Choice Behavior; C	2012
Comparison of substance use milestones in cannabis- and cocaine-dependent patients. Journal of addictive diseases, 2012, Volume: 31, Issue:1 Topics: Adult; Age of Onset; Amines; Antidepressive Agents, Second-Generation; Bupropion; Cocaine-Related Di	2012
Hyponatremia associated with bupropion, a case verified by rechallenge. Journal of clinical psychopharmacology, 2005, Volume: 25, Issue:1 Topics: Alcoholism; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Cocaine-Related D	2005
Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Archives of general psychiatry, 2006, Volume: 63, Issue:2 Topics: Adult; Behavior Therapy; Bupropion; Cocaine; Cocaine-Related Disorders; Combined Modality Therapy; C	2006
Pathological gambling among cocaine-dependent outpatients. The American journal of psychiatry, 2000, Volume: 157, Issue:7 Topics: Adolescent; Adult; Age of Onset; Ambulatory Care; Bromocriptine; Bupropion; Carbamazepine; Cocaine-R	2000
Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers. Drug and alcohol dependence, 2001, Jul-01, Volume: 63, Issue:2 Topics: Administration, Intranasal; Adult; Affect; Arousal; Bupropion; Cocaine; Cocaine-Related Disorders; D	2001
Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. Journal of addictive diseases, 2002, Volume: 21, Issue:2 Topics: Adult; Attention Deficit Disorder with Hyperactivity; Bupropion; Cocaine-Related Disorders; Comorbid	2002

Article	Year
Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. Journal of medicinal chemistry, 2009, Nov-12, Volume: 52, Issue:21 Topics: Adrenergic Uptake Inhibitors; Animals; Bupropion; Cell Line; Cocaine; Cocaine-Related Disorders; Dis	2009
The Persistent Challenge of Developing Addiction Pharmacotherapies. Cold Spring Harbor perspectives in medicine, 2021, 11-01, Volume: 11, Issue:11 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bupropion; Central Nervous System Stimulants; Cocaine-R	2021
Confirmed reports of bupropion sold as crack cocaine in the illicit drug supply. Clinical toxicology (Philadelphia, Pa.), 2021, Volume: 59, Issue:11 Topics: Bupropion; Cocaine-Related Disorders; Crack Cocaine; Drug Trafficking; Gas Chromatography-Mass Spect	2021
Cocaine Abuse, Traumatic Brain Injury, and Preexisting Brain Lesions as Risk Factors for Bupropion-Associated Psychosis. Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:4 Topics: Aged; Brain; Brain Injuries, Traumatic; Bupropion; Cocaine-Related Disorders; Humans; Male; Middle A	2017
Retrospective analysis of health claims to evaluate pharmacotherapies with potential for repurposing: Association of bupropion and stimulant use disorder remission. AMIA ... Annual Symposium proceedings. AMIA Symposium, 2018, Volume: 2018 Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Bupropion; Central Nervous System Stimu	2018
Bupropion perceived as a stimulant by two patients with a previous history of cocaine misuse. Annali dell'Istituto superiore di sanita, 2013, Volume: 49, Issue:4 Topics: Adult; Bupropion; Cocaine-Related Disorders; Dopamine Uptake Inhibitors; Humans; Male; Middle Aged	2013
Pills for speedballing or cocaine dependence. Lancet (London, England), 2006, May-27, Volume: 367, Issue:9524 Topics: Bupropion; Cocaine-Related Disorders; Dopamine Uptake Inhibitors; Humans; Methadone; Narcotics; Opio	2006
Psychosis induced by low-dose bupropion: sensitization of dopaminergic system by past cocaine abuse? Journal of psychiatric practice, 2007, Volume: 13, Issue:5 Topics: Adult; Bupropion; Cocaine; Cocaine-Related Disorders; Delayed-Action Preparations; Dopamine; Dopamin	2007
The search for medications to treat stimulant dependence. Addiction science & clinical practice, 2008, Volume: 4, Issue:2 Topics: Amphetamine-Related Disorders; Benzhydryl Compounds; Brain; Bupropion; Cocaine; Cocaine-Related Diso	2008
Long-acting stimulants for the treatment of attention-deficit disorder in cocaine-dependent adults. Psychiatric services (Washington, D.C.), 2000, Volume: 51, Issue:2 Topics: Adult; Algorithms; Amphetamines; Antidepressive Agents, Second-Generation; Attention Deficit Disorde	2000
Titer-dependent antagonism of cocaine following active immunization in rhesus monkeys. The Journal of pharmacology and experimental therapeutics, 2001, Volume: 296, Issue:3 Topics: Animals; Antibodies; Behavior, Animal; Bupropion; Cocaine; Cocaine-Related Disorders; Dopamine Uptak	2001
Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence. The American journal of drug and alcohol abuse, 2002, Volume: 28, Issue:1 Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Bromocriptine; Bupropion; Cocaine-Relat	2002

bupropion and Cocaine-Related Disorders